ICI-192605
| ICI-192605 | |
|---|---|
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
ICI-192605 is a chemical compound that has been studied for its potential pharmacological effects, particularly as a selective antagonist of the 5-HT2 receptor. This compound was developed by Imperial Chemical Industries (ICI), a company known for its research in pharmaceuticals and chemicals.
Pharmacology[edit]
ICI-192605 is primarily known for its action as a selective antagonist of the 5-HT2 receptor, which is a subtype of the serotonin receptor. The 5-HT2 receptor is involved in various neurological processes, including mood regulation, perception, and cognition. By blocking this receptor, ICI-192605 can potentially alter these processes, making it a compound of interest in the study of psychiatric and neurological disorders.
Mechanism of Action[edit]
The mechanism of action of ICI-192605 involves its binding to the 5-HT2 receptor, preventing serotonin from activating this receptor. This antagonistic action can lead to a decrease in the downstream effects typically mediated by serotonin, such as neurotransmitter release and neuronal excitability.
Potential Applications[edit]
Research into ICI-192605 has suggested potential applications in the treatment of disorders such as schizophrenia, depression, and anxiety disorders. By modulating the serotonergic system, ICI-192605 could help in managing symptoms associated with these conditions.
Chemical Properties[edit]
ICI-192605 is characterized by its specific chemical structure, which allows it to selectively bind to the 5-HT2 receptor. The compound's chemical formula and molar mass are important for understanding its pharmacokinetics and pharmacodynamics.
Research and Development[edit]
The development of ICI-192605 was part of a broader effort to understand the role of serotonin receptors in the brain and to develop drugs that can selectively target these receptors. While ICI-192605 itself may not be used clinically, it has contributed to the understanding of serotonin receptor pharmacology and the development of other therapeutic agents.
Also see[edit]
- 5-HT2 receptor
- Serotonin receptor
- Antagonist (pharmacology)
- Schizophrenia
- Depression
- Anxiety disorders
| Pharmacomodulation | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| Serotonin |
|---|
|
|
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
